We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 431

Omnicare: statements of opinion, omissions, and implications

  • Sidley Austin LLP
  • -
  • USA
  • -
  • March 26 2015

On Tuesday, the Supreme Court issued its decision in Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund, No. 13-435 (U.S

Antitrust enforcement in the medical devices sector

  • Sidley Austin LLP
  • -
  • USA
  • -
  • March 25 2015

Enforcement agencies and courts in the United States have long dealt with high-profile antitrust cases in the pharmaceutical sector. However, until

FDA takes additional steps to address West Africa Ebola outbreak

  • Sidley Austin LLP
  • -
  • Africa, USA
  • -
  • March 25 2015

On March 16, 2015, the Food and Drug Administration (FDA) issued a revised Emergency Use Authorization (EUA) for Corgenix Inc.'s ReEBOV Antigen Rapid

A year of global change 2015: 10 steps multinational life sciences companies should take to address major regulatory challenges in the EU

  • Sidley Austin LLP
  • -
  • European Union
  • -
  • March 5 2015

2015 will be crucial for the EU life sciences regulatory environment. The new European Commission has recently taken up its duties and new priorities

A year of global change 2015: what multinational life sciences companies should expect in China

  • Sidley Austin LLP
  • -
  • China
  • -
  • March 4 2015

With China marching into the Year of the Ram, multinational life sciences companies should anticipate and be prepared for regulatory changes and

A year of global change 2015: 10 steps multinational life sciences companies should take to address global challenges

  • Sidley Austin LLP
  • -
  • Global
  • -
  • March 2 2015

Members of Sidley Austin's Global Life Sciences team recently reviewed litigation, policy, regulatory and enforcement trends on several continents

Human subjects research protections proposed rule finally moves forward for White House review

  • Sidley Austin LLP
  • -
  • USA
  • -
  • February 25 2015

On February 24, the Office of Management and Budget's Office of Internal Regulatory Affairs (OIRA) accepted for review the Department of Health and

Opportunities for participation in the new Precision Medicine Initiative

  • Sidley Austin LLP
  • -
  • USA
  • -
  • February 19 2015

The President recently announced the creation of a new "Precision Medicine Initiative" to "revolutionize how we improve health and treat disease"

Antitrust enforcement in the medical device sector - ten areas of focus in 2015

  • Sidley Austin LLP
  • -
  • China, European Union, USA
  • -
  • February 18 2015

Enforcement agencies and courts in the United States and Europe have long dealt with high-profile antitrust cases in the pharmaceutical sector

CMS delays final overpayments rule until 2016

  • Sidley Austin LLP
  • -
  • USA
  • -
  • February 16 2015

On Friday, February 13, 2015, CMS announced that it needs at least one more year to finalize regulations governing the report and return of